Troglitazone acts on cellular pH and DNA synthesis through a peroxisome proliferator-activated receptor γ-independent mechanism in breast cancer-derived cell lines

Clinical Cancer Research

Volumn 10, Issue 20, 2004, Pages 7022-7030

  Turturro, Francesco ^a   Friday, Ellen ^a   Fowler, Rocky ^a   Surie, Diya ^a   Welbourne, Tomas ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; AMMONIUM CHLORIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA INHIBITOR; PROTEIN INHIBITOR; SODIUM PROTON EXCHANGE PROTEIN 1; TROGLITAZONE; UNCLASSIFIED DRUG;

ACIDOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PH; CELL PROLIFERATION; CELL STRAIN 3T3; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ACIDOSIS; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL PROLIFERATION; CHROMANS; DNA; FEMALE; FIBROBLASTS; HUMANS; HYDROGEN-ION CONCENTRATION; MICE; PPAR GAMMA; THIAZOLIDINEDIONES; TUMOR CELLS, CULTURED;

EID: 6044243631     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0879     Document Type: Article

References (47)

1. Boyer MJ, Tannock IF. Regulation of intracellular pH in tumor cell lines: influence of microenvironmental conditions. Cancer Res 1992;52:4441-7.
2. Lee AH, Tannock IF. Heterogeneity of intracellular pH and of mechanisms that regulate intracellular pH in populations of cultured cells. Cancer Res 1998;58:1901-8.
3. Shrode LD, Tapper H, Grinstein S. Role of intracellular pH in proliferation, transformation, and apoptosis. J Bioenerg Biomembr 1997;29:393-9.
4. Gillies RJ, Martinez-Zaguilan R, Martinez GM, Serrano R, Perona R. Tumorigenic 3T3 cells maintain an alkaline intracellular pH under physiological conditions. Proc Natl Acad Sci USA 1990;87:7414-8.
5. + exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes. FASEB J 2000;14:2185-97.
6. Kallinowski F, Vaupel P, Runkel S, et al. Glucose uptake, lactate release, ketone body turnover, metabolic micromilieu, and pH distributions in human breast cancer xenografts in nude rats. Cancer Res 1988;48:7264-72.
7. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989;49:6449-65.
8. Guppy M, Leedman P, Zu X, Russell V. Contribution by different fuels and metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer cells. Biochem J 2002;364:309-15.
9. Patel AA, Gawlinski ET, Lemieux SK, Gatenby RA. A cellular automaton model of early tumor growth and invasion. J Theor Biol 2001;213:315-31.
10. Gatenby RA, Gawlinski ET. The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res 2003;63:3847-54.
11. Williams AC, Collard TJ, Paraskeva C. An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: implications for clonal selection during colorectal carcinogenesis. Oncogene 1999;18:3199-204.
12. Pouyssegur J, Franchi A, L'Allemain G, Paris S. Cytoplasmic pH, a key determinant of growth factor-induced DNA synthesis in quiescent fibroblasts. FEBS Lett 1985;190:115-9.
13. Lee CH, Cragoe EJ, Edwards AM. Control of hepatocyte DNA synthesis by intracellular pH and its role in the action of tumor promoters. J Cell Physiol 2003;195:61-9.
14. + exchanger for tumor growth. Cancer Res 1989;49:205-11.
15. + exchange, motility, and invasion induced by serum deprivation. J Biol Chem 2000;275:5361-9.
16. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 1989;49:4373-84.
17. Yamagata M, Tannock IF. The chronic administration of drugs that inhibit the regulation of intracellular pH: in vitro and anti-tumour effects. Br J Cancer 1996;73:1328-34.
18. + exchanger (NHE) NHE isoform 1 in human breast cancer cells. Clin Cancer Res 2003;9:2366-73.
19. Altiok S, Xu M, Spiegelman BM. PPARγ induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev 1997;11:1987-98.
20. Camp HS, Li O, Wise SC, et al. Differential activation of peroxisome proliferator-activated receptor-γ by troglitazone and rosiglitazone. Diabetes 2000;49:539-47.
21. de Dios ST, Hannan KM, Dilley RJ, Hill MA, Little PJ. Troglitazone, but not rosiglitazone, inhibits Na/H exchange activity and proliferation of macrovascular endothelial cells. J Diabetes Compl 2001;15:120-7.
22. Isshiki K, Haneda M, Koya D, et al. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 2000;49:1022-32.
23. Benson S, Padmanabhan S, Kurtz TW, Pershadsingh HA. Ligands for the peroxisome proliferator-activated receptor-γ and the retinoid X receptor-α exert synergistic antiproliferative effects on human coronary artery smooth muscle cells. Mol Cell Biol Res Commun 2000;3:159-64.
24. Bruemmer D, Berger JP, Liu J, et al. A non-thiazolidinedione partial peroxisome proliferator-activated receptor γ ligand inhibits vascular smooth muscle cell growth. Eur J Pharmacol 2003;466:225-34.
25. Ghosh SS, Gehr TWB, Ghosh S, et al. PPARγ ligand attenuates PDGF induced mesangial cell proliferation: role of MAP kinase. Kidney Int 2003;64:52-62.
26. Yasunari K, Kohno M, Kano H, et al. Mechanisms of action of troglitazone in the prevention of high glucose-induced migration and proliferation of cultured coronary smooth muscle cells. Circ Res 1997;81:953-62.
27. Clay CE, Namen AM, Atsumi G, et al. Magnitude of peroxisome proliferator-activated receptor-γ activation is associated with important and seemingly opposite biological responses in breast cancer cells. J Investig Med 2001;49:413-20.
28. Mueller E, Sarraf P, Tontonoz P, et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998;1:465-70.
29. Wang C, Fu M, D'Amico M, et al. Inhibition of cellular proliferation through IκB kinase-independent and peroxisome proliferator-activated receptor γ-dependent repression of cyclin D1. Mol Cell Biol 2001;21:3057-70.
30. 1 cell cycle regulators. Biochem Biophys Res Commun 2001;286:916-22.
31. Abe A, Kiriyama Y, Hirano M, et al. Troglitazone suppresses cell growth of KU812 cells independently of PPARγ. Eur J Pharmacol 2002;436:7-13.
32. 1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines. Toxic Lett 2003;139:67-75.
33. Baek SJ, Wilson LC, Hsi LC, Eling TE. Expression of NAG-1, a TGF-beta superfamily member, by troglitazone requires the early growth response gene Egr-1. J Biol Chem 2003;278:5845-53.
34. Palakurthi S, Aktas H, Huseyin A, et al. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation. Cancer Res 2001;61:6213-18.
35. Coates G, Nissim I, Battarbee H, Welbourne T. Glitazones regulate glutamine metabolism by inducing a cellular acidosis in MDCK cells. Am J Physiol 2002;283:E729-37.
36. Welbourne T, Su G, Coates G, et al. Troglitazone induces a cellular acidosis by inhibiting acid extrusion in cultured rat mesangial cells. Am J Physiol 2002;282:R1600-7.
37. Welbourne T, Friday E, Fowler R, Turturro F, Nissim I. Troglitazone acts by PPARγ and PPAR-γ-independent pathways on LLC-PK1-F+ acid-base metabolism. Am J Physiol Renal Physiol 2004;286:F100-10.
38. Routh R, McCarthy K, Welbourne T. Troglitazone inhibits glutamine metabolism in rat mesangial cells. Am J Physiol 2002;282:E231-8.
39. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
40. 2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells. J Biol Chem 2001;276:48950-5.
41. King KL, Cidlowski JA. Cell cycle regulation and apoptosis. Annu Rev Physiol 1998;60:601-17.
42. Matsuyama S, Llopis J, Deveraux QL, Tsien RY, Reed JC. Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis. Nat Cell Biol 2000;2:318-25.
43. + exchanger isoforms. Am J Physiol 1995;268:C283-96.
44. Doppler WR, Jaggi R, Groner B. Induction of v-mos and activated Ha-ras oncogene expression in quiescent NIH3T3 cells cause intracellular alkalinisation and cell-cycle progression. Gene (Amst) 1987;54:14715-3.
45. 3 exchange in NIH-3T3 fibroblasts. J Biol Chem 1994;269:4116-24.
46. Wahl ML, Owen JA, Burd R, et al. Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol Cancer Ther 2002;1:617-28.
47. Preisig P. A cell cycle-dependent mechanism of renal tubule epithelial cell hypertrophy. Kidney Int 1999;56:1193-8.